Viewing Study NCT05654532

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:34 PM
Ignite Modification Date: 2026-02-18 @ 2:10 PM
Study NCT ID: NCT05654532
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-09-30
First Post: 2022-12-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
Sponsor: Accutar Biotechnology Inc
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast Cancer View
None Estrogen receptor-positive breast cancer View
None ER positive View
None ER+ View
None Human epidermal growth factor receptor 2 negative View
None HER2 negative breast cancer View
None HER2- View
None AC699 View
None Metastatic breast cancer View
None MBC View
None Locally advanced breast cancer View
None ER chimeric degrader View
None ER degrader View